Related Experiment Videos
Protected environment-prophylactic antibiotic program for malignant lymphoma. Randomized trial during chemotherapy to
The American Journal of Medicine
|January 1, 1979
Summary
The protected environment-prophylactic antibiotic (PEPA) program reduced infections in malignant lymphoma patients but did not improve remission rates. Dosage escalation, however, significantly reduced relapse and fatality rates, improving survival.
Area of Science:
- Oncology
- Hematology
- Infectious Disease
Background:
- Malignant lymphoma patients undergoing chemotherapy face high risks of infection.
- The protected environment-prophylactic antibiotic (PEPA) program aims to mitigate these risks.
- Optimizing chemotherapy delivery is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of the PEPA program in reducing infections during chemotherapy for malignant lymphoma.
- To assess the impact of the PEPA program and chemotherapy dosage escalation on remission rates, relapse, and survival.
Main Methods:
- Randomized controlled trial involving 58 patients with malignant lymphoma.
- Patients were assigned to either the PEPA program or a control group.
- Chemotherapy regimen included CHOP-Bleo for remission induction.
Main Results:
- The PEPA program significantly reduced infection frequency compared to controls.
- No significant differences in complete remission rates or response duration were observed between PEPA and control groups.
- Chemotherapy dosage escalation, facilitated by the PEPA program, reduced relapse and fatality rates, and prolonged remission duration and survival.
Conclusions:
- The PEPA program effectively reduces infections in lymphoma patients undergoing chemotherapy.
- While not directly improving remission rates, the PEPA program enables chemotherapy dosage escalation.
- Dosage escalation is a key factor in reducing relapse and fatality, thereby improving long-term survival in malignant lymphoma.